Zeba's Feed
Jul 24, 2015

Funding crisis puts India’s AIDS programme, and lives, at risk

NEW DELHI/MUMBAI (Reuters) – India’s fight against AIDS is being jeopardised by a cut in social spending by Prime Minister Narendra Modi’s government, with health workers being laid off and programmes to prevent the spread of the deadly disease curtailed.

With about 2.1 million people infected with HIV in 2013, India has the most cases in the Asia-Pacific, according to the World Health Organisation, but new infections have fallen more than 20 percent over the past 14 years.

Jul 23, 2015

Lupin looks to revive U.S. growth with $880 mln GAVIS deal

MUMBAI (Reuters) – Lupin Ltd (LUPN.NS: Quote, Profile, Research, Stock Buzz), India’s third-largest drugmaker by sales, is buying U.S. peer GAVIS Pharmaceuticals LLC for $880 million in its largest ever acquisition, seeking to revive its flagging growth in the United States, its largest market.

The acquisition will give Mumbai-based Lupin access to a number of speciality generic drugs that tend to command a higher price as they are used to treat niche diseases.

Jul 23, 2015

India’s Lupin looks to revive U.S. growth with $880 mln GAVIS deal

MUMBAI, July 23 (Reuters) – Lupin Ltd, India’s
third-largest drugmaker by sales, is buying U.S. peer GAVIS
Pharmaceuticals LLC for $880 million in its largest ever
acquisition, seeking to revive its flagging growth in the United
States, its largest market.

The acquisition will give Mumbai-based Lupin access to a
number of speciality generic drugs that tend to command a higher
price as they are used to treat niche diseases.

Jul 17, 2015

India expands medicine price control list to include 2 antibiotics

MUMBAI, July 16 (Reuters) – India has extended price caps to
an additional two antibiotics, in the government’s latest effort
to improve the affordability of medicines.

India’s National Pharmaceutical Pricing Authority (NPPA)
said in a notice that it had put price caps on the 250 mg
strength of ciprofloxacin hydrochloride and the 250 mg and 500
mg strengths of cefotaxime.

Jul 16, 2015

Supreme Court court seeks review of drug pricing policy

MUMBAI (Reuters) – The Supreme Court has asked the central government to reexamine its pricing policy for essential medicines after a group of non-governmental organisations challenged the provisions, a lawyer involved in the case said.

The Supreme Court labelled the formula by which prices of essential medicines are currently being fixed in India as “unreasonable and irrational”, the lawyer said.

Jul 16, 2015

India’s top court seeks review of drug pricing policy

MUMBAI, July 16 (Reuters) – India’s Supreme Court has asked
the federal government to reexamine its pricing policy for
essential medicines after a group of non-governmental
organisations challenged the provisions, a lawyer involved in
the case said.

The Supreme Court labelled the formula by which prices of
essential medicines are currently being fixed in India as
“unreasonable and irrational”, the lawyer said.

Jul 16, 2015

India expands medicine price control list to include 39 more drugs

MUMBAI (Reuters) – India has extended price caps to an additional 39 drugs ranging from commonly used diabetes treatments to antibiotics, in the government’s latest effort to improve the affordability of medicines.

Wide-ranging price cuts over the past year have hit several drugmakers in India and have been opposed by many in the industry, who say drug prices in the country are already among the lowest in the world. The new drugs join a price control list that covers more than 500 drugs.

Jul 10, 2015

Regulators tighten scrutiny of India clinical research firms

MUMBAI/LONDON (Reuters) – The U.S. Food and Drug Administration (FDA) and the World Health Organisation have intensified investigations into India’s clinical research firms, industry officials said, after recent probes revealed two leading firms had violated standards.

The scrutiny is likely to further hurt India’s reputation as a global pharmaceutical hub, as it follows sanctions imposed by the FDA and other regulators on Indian generic drugmakers over manufacturing quality lapses.

Jul 7, 2015

Another Indian firm under fire for shoddy clinical trials work

LONDON/MUMBAI (Reuters) – Another Indian clinical research organisation, Quest Life Sciences of Chennai, is in trouble over defective trials work, according to a warning issued by the World Health Organization.

The action by the United Nations health agency follows an earlier scandal over drug testing at GVK Biosciences, which resulted in approvals for hundreds of generic drugs being withdrawn in Europe.

Jun 28, 2015

Indian pharma’s struggle to tighten standards paves way for M&A deals

MUMBAI (Reuters) – India’s smaller generic drugmakers, struggling to cope with a bruised reputation and tougher regulation in the United States, are under pressure to consider branching out to new, less-profitable markets or sell out to larger rivals.

Two years after its most high-profile regulatory setback to date in the United States – Ranbaxy’s (RANB.NS: Quote, Profile, Research, Stock Buzz) $500 million U.S. fine for drug safety violations – India’s $15 billion a year generic drug industry is still rebuilding its image in its biggest market.

    • About Zeba

      "Zeba is responsible for covering India's thriving pharmaceuticals and healthcare industries from Mumbai. She earlier reported on U.S. biotechnology and healthcare companies from the Bangalore bureau. She holds a post-graduate degree in journalism from India, and is fluent in Hindi, Urdu and Marathi."
      Joined Reuters:
      2011
    • More from Zeba

    • Contact Zeba

    • Follow Zeba